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Sara Courtneidge has recently been
appointed vice-president of research
in the California-based biotechnology
company, Sugen, Inc. Her pioneering
research into how the Src tyrosine
kinase is involved in cellular
transformation has provided the basis
for understanding how members of
the src gene family act in normal
signal transduction pathways. In her
new position, Dr Courtneidge will be
trying to identify components of
signal transduction pathways as targets
for pharmaceutical intervention.
Dr Courtneidge’s career began
when, at the age of eight, she
announced that she was going to be a
scientist. Thirteen years later, she
obtained an Honours degree in
Biochemistry at the University of
Leeds and moved to the National
Institute for Medical Research
(NIMR) at Mill Hill, England for her
doctoral studies. There, under the
supervision of Mike Crumpton and
John Skehel, she studied how cells
infected with influenza virus are
recognized and destroyed by cytotoxic
T cells. During this time, Dr
Courtneidge’s critical and analytical
skills were sharpened by the continual
barrage of questions on seminars and
papers from John Skehel, who worked
on the lab bench opposite hers.
Throughout her postgraduate studies,
Dr Skehel encouraged her to think
about her future scientific direction, a
process that resulted in her securing a
postdoctoral research position in J.
Michael Bishop’s lab at the University
of California, San Francisco. 
Having only ever spoken to Dr
Bishop on the telephone, Dr
Courtneidge was initially over-
whelmed on her arrival at the lab in
San Francisco. The combined Bishop
and Varmus laboratories were, at that
time, beginning to identify the
cellular genes that had been
incorporated into RNA tumour viruses
and which gave them the ability to
transform cells. This was, and has
continued to be, a large, energetic
laboratory at the cutting edge of
molecular biology research and Dr
Courtneidge was the youngest and
newest member. However, she soon
adjusted to the dynamic environment
and began her work on identifying the
structural and functional domains of
the transforming protein isolated from
Rous sarcoma virus, pp60v-src, or Src. 
On her return to England, she was
offered a junior staff position at
NIMR where, together with Alan
Smith, she demonstrated that the
transforming protein of polyomavirus,
middle T antigen, acquired its
tyrosine kinase activity by association
with the cellular homologue of
pp60v-src. From this work, Dr
Courtneidge was inspired to examine
the normal role of the Src protein in
cells and discovered that the cellular
Src protein is, itself, negatively
regulated by tyrosine phosphorylation.
In the mid-1980s, Dr Courtneidge
accepted an offer to join the
European Molecular Biology
Laboratories (EMBL) in Heidelberg,
Germany. The organization of
EMBL, with several, small
interactive research groups and a
multi-cultural composition, provided
an exciting and stimulating backdrop
for Dr Courtneidge to develop her
research interests. During this time, a
number of groups throughout the
world began to identify other cellular
tyrosine kinases that were related to,
and shared certain domains with, the
cellular Src protein. Dr Courtneidge’s
laboratory demonstrated that these
proteins were absolutely required for
the normal control of cellular growth.
She also showed that members of this
family were components of normal
signal transduction pathways,
regulating the pathways by virtue of
their kinase activity. This provided a
valuable means for studying how
cellular growth is regulated in normal
cells and also how this regulation is
disrupted in transformed cells. 
Despite having the rare privilege
of an open-ended position at EMBL,
Dr Courtneidge recently decided it
was time for a new challenge. This
came in the form of an offer to direct
the research division of Sugen, Inc.
There, her laboratory will be trying to
identify components of signal
transduction pathways which can act
as new therapeutic targets for the
treatment of diseases such as cancer.
While there is no doubt that the
application of her work to a
commercial setting will be very
challenging, Dr Courtneidge has
successfully been swimming with Srcs
for most of her research career and has
always managed to tame them. 
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